Estrogens

Estrogens are used in hormone replacement therapy and contraceptives. They interact with CYP450 inducers that reduce their effectiveness, anticoagulants, and thyroid medications.

18 drugs in this class6 notable interactions shown

Estrogens Drugs (18)

Conjugated Estrogens And Medroxyprogesterone AcetatePrempro Conjugated Estrogens/BazedoxifeneDuavee Drospirenone And EstradiolAngeliq EstradiolClimara Estradiol And LevonorgestrelClimara Pro Estradiol And Norethindrone AcetateAbigale Lo Estradiol And ProgesteroneBijuva Estradiol Gel 0.1%Estradiol Estradiol TransdermalEstradiol Estradiol/Norethindrone Acetate Transdermal SystemCombipatch (Estradiol/Norethindrone Acetate Transdermal System)Estrogens, ConjugatedPremarin Etonogestrel And Ethinyl EstradiolNuvaring Etonogestrel And Ethinyl Estradiol Vaginal RingEtonogestrel And Ethinyl Estradiol Vaginal Ring Levonorgestrel/Ethinyl Estradiol And Ethinyl EstradiolRivelsa Norelgestromin And Ethinyl EstradiolZafemy Norethindrone Acetate/Ethinyl EstradiolFemlyv Norethindrone And Ethinyl EstradiolWymzya Fe Segesterone Acetate And Ethinyl EstradiolAnnovera

Notable Estrogens Interactions

Conjugated Estrogens And Medroxyprogesterone Acetate + Aminoglutethimide⚠️Major

Significantly depresses the bioavailability of medroxyprogesterone acetate when administered concomitantly.

Conjugated Estrogens And Medroxyprogesterone Acetate + Carbamazepine🟡Moderate

CYP3A4 inducer may reduce plasma concentrations of estrogens, possibly decreasing therapeutic effects and/or altering uterine bleeding profile.

Conjugated Estrogens And Medroxyprogesterone Acetate + Clarithromycin🟡Moderate

CYP3A4 inhibitor may increase plasma concentrations of estrogens and may result in side effects.

Conjugated Estrogens/Bazedoxifene + Carbamazepine🟡Moderate

CYP3A4 and UGT inducer may reduce estrogen and bazedoxifene concentrations, decreasing therapeutic effects and increasing endometrial hyperplasia risk.

Conjugated Estrogens/Bazedoxifene + Itraconazole🟡Moderate

Strong CYP3A4 inhibitor increases bazedoxifene exposure (40%) and conjugated estrogens exposure (5-9%), potentially increasing drug effects.

Conjugated Estrogens/Bazedoxifene + Phenobarbital🟡Moderate

CYP3A4 and UGT inducer may reduce estrogen and bazedoxifene concentrations, decreasing therapeutic effects and increasing endometrial hyperplasia risk.

Check Your Estrogens Interactions

Enter your specific medications to see all interactions — including combinations with Estrogens drugs.

Check Interactions →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.